1-6 of 6
Ola Linden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

90 Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, MD, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1806.
https://doi.org/10.1182/blood.V128.22.1806.1806
Published: 2016
Journal Articles

Follicular Lymphoma Survival in Sweden in the Rituximab Era

Henna Riikka Junlén, MD, Stefan Peterson, Eva Kimby, Sandra Lockmer, MD, Ola Linden, MD, Herman Nilsson-Ehle, MD PhD, Martin Erlanson, Hans Hagberg, Anders Rådlund, Oskar Hagberg, Björn E Wahlin, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1758.
https://doi.org/10.1182/blood.V124.21.1758.1758
Published: 2014
Journal Articles

More Sun Light Exposure May Be Associated with Improved Overall Survival in Diffuse Large B-Cell Lymphoma. A Population Based Swedish Lymphoma Registry Study

Mats Jerkeman, Elisabeth Székely, MD, Oskar Hagberg, Ola Linden, MD
Journal: Blood
Blood (2012) 120 (21): 4847.
https://doi.org/10.1182/blood.V120.21.4847.4847
Published: 2012
Journal Articles

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Eva Kimby, M.D., Ph.D., Björn Östenstad, Peter de Nully Brown, Harald Holte, Jr., MD, PhD, Hans Hagberg, Martin Erlanson, Ola Linden, MD, Marie Nordström, MD, PhD, Christer Sundstrom, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 794.
https://doi.org/10.1182/blood.V120.21.794.794
Published: 2012
Journal Articles

90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial

Christian W. Scholz, MD, Antonello Pinto, MD, Werner Linkesch, MD, Ola Linden, MD, Andreas Viardot, MD, Ulrich Keller, MD, Georg Hess, MD, Kristina Lerch, MD, Ferdinando Frigeri, MD, Manuela Arcamone, MD, Bernd Frericks, MD, Christiane Pott, MD, Antonio Pezzutto
Journal: Blood
Blood (2010) 116 (21): 593.
https://doi.org/10.1182/blood.V116.21.593.593
Published: 2010
Journal Articles

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Paula Marlton, Umberto Vitolo, Ola Linden, John Seymour, Michael Crump, Bertrand Coiffier, Alessandro Pulsoni, Andrew Belch, Erika Lerch, Eva Kimby, Kristina Arnljots, Elisabeth Wassner, Myriam Mendila
Journal: Blood
Blood (2007) 110 (11): 645.
https://doi.org/10.1182/blood.V110.11.645.645
Published: 2007